Power Law company profile

New Horizon Health

Biotech & Life Sciences · Hangzhou, China · Founded 2015 · IPO 2021 Thoroughbred

Researches and develops technology for early-stage cancer screening

Valuation

$806M

Market cap · 2026

Revenue

$105M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

13 investors on New Horizon Health's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

SB China Capital

Legend Capital

Series B+ 11 investors entered at this stage

Rock Springs Capital

Cormorant Asset Management

Octagon Capital Partners

Lilly Asia Ventures

Exome Asset Management

OrbiMed

OmniScience

Zhejiang University

Qiming Venture Partners

VMS Group

VMS Investment Group

Global footprint

Where New Horizon Health has talent and traffic

Workforce by country

🇨🇳 China · Hangzhou HQ

Book a demo for the full country breakdown

Web traffic by country

7.8K monthly visits
across markets

🇨🇳 China100%

Top 1 markets shown

Market sentiment

What the market is saying about New Horizon Health

An AI-synthesized read of the highest-engagement posts about New Horizon Health on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See New Horizon Health on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles